Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 1
Submit an article Journal homepage
582
Views
17
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades

Tiantian SunDepartment of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;
,
Shuncong WangDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China;
,
Huanhuan SunDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China;
,
Jianguo WenDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA;
,
Gang AnState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China
&
Juan LiDepartment of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Correspondence[email protected]
Pages 49-58 | Received 09 Mar 2017, Accepted 21 May 2017, Published online: 09 Jun 2017

References

  • Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
  • Mian I, Milton DR, Shah N, et al. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016;122:3831–3837.
  • Wang S, Sun H, Xie Z, et al. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983–2012. Oncotarget. 2016;7:59820–59833.
  • Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412–9420.
  • Krieger N, Chen JT, Waterman PD, et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol. 2002;156:471–482.
  • Krieger N, Chen JT, Waterman PD, et al. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures–the public health disparities geocoding project. Am J Public Health. 2003;93:1655–1671.
  • Velez R, Turesson I, Landgren O, et al. Incidence of multiple myeloma in Great Britain, Sweden, and Malmo, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open. 2016;6:e009584.
  • Renshaw C, Ketley N, Moller H, et al. Trends in the incidence and survival of multiple myeloma in South East England 1985–2004. BMC Cancer. 2010;10:74.
  • Sola B, Renoir JM. Estrogenic or antiestrogenic therapies for multiple myeloma? Mol Cancer. 2007;6:59.
  • Baker A, Braggio E, Jacobus S, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121:3147–3152.
  • Zwick C, Held G, Auth M, et al. Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM. Int J Cancer. 2014;135:934–938.
  • Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882–885.
  • Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11.
  • Kyle RA. The role of bisphosphonates in multiple myeloma. Ann Intern Med. 2000;132:734–736.
  • Kusumi E, Matsumura T, Yuji K, et al. Thalidomide in elderly patients with multiple myeloma. Lancet. 2006;367:1977. Author reply 1977–1978.
  • Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–2085.
  • Meijer E, Sonneveld P. Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. Nat Rev Clin Oncol. 2009;6:247–248.
  • Johnson DC, Weinhold N, Mitchell JS, et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016;7:10290.
  • Ziv E, Dean E, Hu D, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015;6:7539.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.